{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:03:04Z","timestamp":1792000984770,"version":"4.4.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12969-017-0147-3","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T03:24:29Z","timestamp":1489461869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis"],"prefix":"10.1186","volume":"15","author":[{"given":"Boris","family":"H\u00fcgle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Speth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes-Peter","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,14]]},"reference":[{"key":"147_CR1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nrrheum.2011.68","volume":"7","author":"ED Mellins","year":"2011","unstructured":"Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7:416\u201326.","journal-title":"Nat Rev Rheumatol"},{"key":"147_CR2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, Cortis E, Pardeo M, Miettunen PM, Janow G, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545\u201355.","journal-title":"Arthritis Rheum"},{"key":"147_CR3","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396\u2013406.","journal-title":"N Engl J Med"},{"key":"147_CR4","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/archdischild-2011-300633","volume":"96","author":"MD Kappelman","year":"2011","unstructured":"Kappelman MD, Galanko JA, Porter CQ, Sandler RS. Association of paediatric inflammatory bowel disease with other immune-mediated diseases. Arch Dis Child. 2011;96:1042\u20136.","journal-title":"Arch Dis Child"},{"key":"147_CR5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/03009740701394005","volume":"36","author":"J Kokkonen","year":"2007","unstructured":"Kokkonen J, Arvonen M, Vahasalo P, Karttunen TJ. Intestinal immune activation in juvenile idiopathic arthritis and connective tissue disease. Scand J Rheumatol. 2007;36:386\u20139.","journal-title":"Scand J Rheumatol"},{"key":"147_CR6","doi-asserted-by":"crossref","unstructured":"Pichler J, Ong C, Shah N, Sebire N, Kiparrissi F, Borrelli O, Pilkington C, Elawad M. Histopathological features of gastrointestinal mucosal biopsies in children with juvenile idiopathic arthritis. Pediatr Res. 2016.","DOI":"10.1038\/pr.2016.27"},{"key":"147_CR7","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3899\/jrheum.100809","volume":"38","author":"TD Dijken van","year":"2011","unstructured":"van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2011;38:1441\u20136.","journal-title":"J Rheumatol"},{"key":"147_CR8","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/rheumatology\/keq136","volume":"49","author":"A Dallocchio","year":"2010","unstructured":"Dallocchio A, Canioni D, Ruemmele F, Duquesne A, Scoazec JY, Bouvier R, Paraf F, Languepin J, Wouters CH, Guillot M, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology (Oxford). 2010;49:1694\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"147_CR9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005176-200408000-00016","volume":"39","author":"FM Ruemmele","year":"2004","unstructured":"Ruemmele FM, Prieur AM, Talbotec C, Goulet O, Schmitz J. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J Pediatr Gastroenterol Nutr. 2004;39:203\u20136.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"147_CR10","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.3899\/jrheum.140472","volume":"42","author":"D Barthel","year":"2015","unstructured":"Barthel D, Ganser G, Kuester RM, Onken N, Minden K, Girschick HJ, Hospach A, Horneff G. Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol. 2015;42:2160\u20135.","journal-title":"J Rheumatol"},{"key":"147_CR11","first-page":"1567","volume":"20","author":"H Mielants","year":"1993","unstructured":"Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, Maertens M, Joos R. Gut inflammation in children with late onset pauciarticular juvenile chronic arthritis and evolution to adult spondyloarthropathy--a prospective study. J Rheumatol. 1993;20:1567\u201372.","journal-title":"J Rheumatol"},{"key":"147_CR12","doi-asserted-by":"crossref","first-page":"e54562","DOI":"10.1371\/journal.pone.0054562","volume":"8","author":"F Zorzi","year":"2013","unstructured":"Zorzi F, Monteleone I, Sarra M, Calabrese E, Marafini I, Cretella M, Sedda S, Biancone L, Pallone F, Monteleone G. Distinct profiles of effector cytokines mark the different phases of Crohn\u2019s disease. PLoS One. 2013;8:e54562.","journal-title":"PLoS One"},{"key":"147_CR13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.25.022106.141627","volume":"27","author":"SL Masters","year":"2009","unstructured":"Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol. 2009;27:621\u201368.","journal-title":"Annu Rev Immunol"},{"key":"147_CR14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01993274","volume":"34","author":"TK Thomas","year":"1991","unstructured":"Thomas TK, Will PC, Srivastava A, Wilson CL, Harbison M, Little J, Chesonis RS, Pignatello M, Schmolze D, Symington J, et al. Evaluation of an interleukin-1 receptor antagonist in the rat acetic acid-induced colitis model. Agents Actions. 1991;34:187\u201390.","journal-title":"Agents Actions"},{"key":"147_CR15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/MOG.0000000000000118","volume":"30","author":"G Bamias","year":"2014","unstructured":"Bamias G, Arseneau KO, Cominelli F. Cytokines and mucosal immunity. Curr Opin Gastroenterol. 2014;30:547\u201352.","journal-title":"Curr Opin Gastroenterol"},{"key":"147_CR16","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/gutjnl-2012-303329","volume":"63","author":"M Bersudsky","year":"2014","unstructured":"Bersudsky M, Luski L, Fishman D, White RM, Ziv-Sokolovskaya N, Dotan S, Rider P, Kaplanov I, Aychek T, Dinarello CA, et al. Non-redundant properties of IL-1alpha and IL-1beta during acute colon inflammation in mice. Gut. 2014;63:598\u2013609.","journal-title":"Gut"},{"key":"147_CR17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2739\/kurumemedj.45.33","volume":"45","author":"S Kuboyama","year":"1998","unstructured":"Kuboyama S. Increased circulating levels of interleukin-1 receptor antagonist in patients with inflammatory bowel disease. Kurume Med J. 1998;45:33\u20137.","journal-title":"Kurume Med J"},{"key":"147_CR18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/01.RHU.0000081265.06408.e4","volume":"9","author":"JD Carter","year":"2003","unstructured":"Carter JD, Valeriano J, Vasey FB. Crohn disease worsened by anakinra administration. J Clin Rheumatol. 2003;9:276\u20137.","journal-title":"J Clin Rheumatol"},{"key":"147_CR19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747\u201354.","journal-title":"Ann Rheum Dis"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-017-0147-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T12:33:47Z","timestamp":1498394027000},"score":1,"resource":{"primary":{"URL":"http:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-017-0147-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,14]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["147"],"URL":"https:\/\/doi.org\/10.1186\/s12969-017-0147-3","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,14]]},"article-number":"16"}}